Thyroid Hormone Analogues: An Update
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The development of thyroid hormone (TH) analogues was prompted by the attempt to exploit the effects of TH on lipid metabolism, avoiding cardiac thyrotoxicosis. Analysis of the relative distribution of the α and β subtypes of nuclear TH receptors (TRα and TRβ) showed that TRα and TRβ are responsible for cardiac and metabolic responses, respectively. Therefore, analogues with TRβ selectivity were developed, and four different compounds have been used in clinical trials: GC-1 (sobetirome), KB-2115 (eprotirome), MB07344/VK2809, and MGL-3196 (resmetirom). Each of these compounds was able to reduce low-density lipoprotein cholesterol, but a phase 3 trial with eprotirome was interrupted because of a significant increase in liver enzymes and the contemporary report of cartilage side effects in animals. As a consequence, the other projects were terminated as well. However, in recent years, TRβ agonists have raised new interest for the treatment of nonalcoholic fatty liver disease (NAFLD). After obtaining excellent results in experimental models, clinical trials have been started with MGL-3196 and VK2809, and the initial reports are encouraging. Sobetirome turned out to be effective also in experimental models of demyelinating disease. Aside TRβ agonists, TH analogues include some TH metabolites that are biologically active on their own, and their synthetic analogues. 3,5,3'-triiodothyroacetic acid has already found clinical use in the treatment of some cases of TH resistance due to TRβ mutations, and interesting results have recently been reported in patients with the Allan-Herndon-Dudley syndrome, a rare disease caused by mutations in the TH transporter MCT8. 3,5-diiodothyronine (T2) has been used with success in rat models of dyslipidemia and NAFLD, but the outcome of a clinical trial with a synthetic T2 analogue was disappointing. 3-iodothyronamine (T1AM) is the last entry in the group of active TH metabolites. Promising results have been obtained in animal models of neurological injury induced by β-amyloid or by convulsive agents, but no clinical data are available so far.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802
Thyroid hormone receptors and resistance to thyroid hormone disorders
Ortiga-Carvalho, T. M., Sidhaye, A. R., & Wondisford, F. E. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.143 · Cited by 383
Trace amine-associated receptors and their ligands
Zucchi, R., Chiellini, G., Scanlan, T. S., & Grandy, D. K. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706948 · Cited by 314
Self-citationAdrenoleukodystrophy—Neuroendocrine pathogenesis and redefinition of natural history
Kemp, S., Huffnagel, I. C., Linthorst, G. E., Wanders, R. J., & Engelen, M. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.90 · Cited by 275
The Case for TAAR1 as a Modulator of Central Nervous System Function
Rutigliano, G., Accorroni, A., & Zucchi, R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00987 · Cited by 166
Self-citationThyroid Hormone Signaling Pathways: Time for a More Precise Nomenclature
Flamant, F., Cheng, S.-Y., Hollenberg, A. N., Moeller, L. C., Samarut, J., Wondisford, F. E., Yen, P. M., & Refetoff, S. (2017) · Endocrinology · doi:10.1210/en.2017-00250 · Cited by 165 · cited 1×
“In addition to canonical signaling, TH may activate a number of noncanonical signaling pathways (2).”
BackgroundDiiodothyropropionic acid (DITPA) in the treatment of MCT8 deficiency
Verge, C. F., Konrad, D., Cohen, M., Di Cosmo, C., Dumitrescu, A. M., Marcinkowski, T., Hameed, S., Hamilton, J., Weiss, R. E., & Refetoff, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2556 · Cited by 134 · cited 1×
“4 mg/kg per day) was able to normalize T3 in four children affected by MCT8 deficiency, aged 8–25 months (34).”
BackgroundGroeneweg, S., Peeters, R. P., Moran, C., Stoupa, A., Auriol, F., Tonduti, D., Dica, A., Paone, L., Rozenkova, K., Malikova, J., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30155-x · Cited by 129
Jonas, W., Lietzow, J., Wohlgemuth, F., Hoefig, C. S., Wiedmer, P., Schweizer, U., Köhrle, J., & Schürmann, A. (2015) · Endocrinology · doi:10.1210/en.2014-1604 · Cited by 90
Cited by
Mitochondrial alterations in fatty liver diseases
Fromenty, B., & Roden, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.09.020 · Cited by 424
Non-genetic influences on lipoprotein(a) concentrations
Enkhmaa, B., & Berglund, L. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.006 · Cited by 193
Kokkorakis, M., Boutari, C., Hill, M. A., Kotsis, V., Loomba, R., Sanyal, A. J., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155835 · Cited by 155
Saponaro, F., Sestito, S., Runfola, M., Rapposelli, S., & Chiellini, G. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00331 · Cited by 124
“The aim of the present review is to provide an update regarding the most significant steps toward the obtainment of clinically useful thyromimetics, providing further details on a subject that has already been widely discussed in recent reviews (25, 26).”
BackgroundNAFLD and thyroid function: pathophysiological and therapeutic considerations
Hatziagelaki, E., Paschou, S. A., Schön, M., Psaltopoulou, T., & Roden, M. (2022) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2022.08.001 · Cited by 93
“Phase 1a and 1b clinical trials examined the efficacy, safety, and tolerability of MB07811 [108,109], but the Phase 2 clinical trial of MB07344 was terminated even before initiation for reasons undisclosed to the public [86,109].”
BackgroundInfluential
Metadata
- Authors
- Zucchi, R.
- Venue
- Thyroid
- Publisher
- SAGE Publications
- Published
- 2020-08-01
- Volume
- 30
- Issue
- 8
- Pages
- 1099-1105
- ISSN
- 1050-7256 (ISSN-L)
- 1557-9077
- OpenAlex
- W3007426568
- Cited by
- 87
- References
- 12
- FWCI
- 5.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.